The purpose of this study is to evaluate the association between complex patterns of device-detected AF and other summary and episodic measurements collected by the LINQ ICM device and AF-related healthcare utilization, quality of life, AF-related symptoms, and specific clinical outcomes in patients with a market-released LINQ ICM.


  • Patients with a LINQ ICM who have a self-reported history of AF and who have received an ICM for the following device-logged indications, categorized into the following discreet groups:
    • Stroke: Cryptogenic stroke indications
    • AF management: AF management and post-ablation management indications
    • Suspected AF: Suspected AF and palpitations indications
  • Individual Access and ability to use an Apple iPhone® compatible with Medtronic’s research app (iOS v. 13.X or higher)
  • Patient is willing and able to comply with the  protocol, including CareLink transmissions (requires adequate connectivity), remotely administered instructions, and remote survey participation
  • Self-reported virtual CHA2DS2-VASc score ≥2 for men and ≥3 for women
  • Patient is 22 years of age or older
  • Located in the United States, with CareLink managed through servers located in United States (50 states or District of Columbia)
  • Valid email address from self-report at enrollment
  • Patient must be able to read and write in English